Adiponectin Tied to Increased CV Risk in T2DM, Acute Coronary Sx

This article originally appeared here.
Share this content:
Adiponectin Tied to Increased CV Risk in T2DM, Acute Coronary Sx
Adiponectin Tied to Increased CV Risk in T2DM, Acute Coronary Sx

WEDNESDAY, Feb. 22, 2017 (HealthDay News) -- For patients with type 2 diabetes and acute coronary syndrome (ACS), adiponectin concentration is associated with increased risk of certain cardiovascular (CV) outcomes, according to a study published online Feb. 14 in Diabetes, Obesity and Metabolism.

Brian A. Bergmark, M.D., from the Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues examined adiponectin and CV outcomes in 5,213 patients with type 2 diabetes enrolled 15 to 90 days after ACS. The authors assessed event rates at 18 months.

The researchers found that, compared to patients with baseline adiponectin in the lowest quartile, patients with the highest baseline adiponectin concentration (Q4) had significantly increased risks of CV death (8.4 versus 1.7 percent), hospitalization for heart failure (7.5 versus 1.7 percent), and all-cause mortality (10.8 versus 2.4 percent) (all P < 0.0001). The significant associations persisted after adjustment for age, sex, index event, heart failure, estimated glomerular filtration rate, and hypertension, with hazard ratios of 2.43, 2.45, and 2.44 for CV death, all-cause mortality, and heart failure, respectively, for adiponectin concentration in Q4, without change after stratification by body mass index. The rate of myocardial infarction or stroke did not differ significantly.

"Adiponectin concentration was independently associated with increased risk of CV death, all-cause mortality, and heart failure hospitalization," the authors write. "The relationship between adiponectin and CV outcomes is complex and deserves further study."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

FDA OKs Lynparza to Treat Breast Cancer With BRCA Mutation

FDA OKs Lynparza to Treat Breast Cancer With ...

PARP inhibitor therapy already approved to treat BRCA-mutated ovarian cancer

Ceramide-Infused Skin Barrier Cuts Stoma-Related Costs

Ceramide-Infused Skin Barrier Cuts Stoma-Related Costs

Use of ceramide-infused barrier tied to lower stoma-related care costs, improved patient satisfaction

Non-Ventilator Hospital-Acquired Pneumonia Risk Affects All Ages

Non-Ventilator Hospital-Acquired Pneumonia Risk Affects All Ages

Non-vent-associated HAP risk occurs in all hospital units; risk extends even to low-risk/younger patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »